Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study of the Safety and Efficacy of Non-viral Site-directed Integrated PD1-BCMA-CART in Adult Treatment of Relapsed or Refractory Multiple Myeloma

Next Previous
Trial Profile

Clinical Study of the Safety and Efficacy of Non-viral Site-directed Integrated PD1-BCMA-CART in Adult Treatment of Relapsed or Refractory Multiple Myeloma

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-PD1 BCMA chimeric antigen receptor T cell therapy-Shanghai Bioray Laboratory (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors BRL Medicine

Most Recent Events

  • 04 Jan 2024 Planned initiation date changed from 1 Nov 2023 to 1 Mar 2024.
  • 21 Jul 2023 Planned End Date changed from 1 Jun 2025 to 1 Oct 2025.
  • 21 Jul 2023 Planned initiation date changed from 1 Dec 2022 to 1 Nov 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top